A standard operating microscope was modified with a bandpass infrared filter in the light path and infrared image intensifiers for each of the 2 eyepieces. We evaluated this system for subretinal injections in normal control dogs and those with a mutation in the rhodopsin gene. Rhodopsin-mutant dogs are a model for human autosomal dominant retinitis pigmentosa, and their retinas degenerate faster when exposed to modest light levels as used in routine clinical examinations. We showed that the mutant retinas developed severe generalized degeneration when exposed to the standard operating microscope light but not the infrared light. The modified operating microscope provided an excellent view of the ocular fundus under infrared illumination and allowed us to perform subretinal injections in the retinas of the rhodopsin-mutant dogs without any subsequent light-induced retinal degeneration.
The Zeiss OPMI 6 operating microscope (Carl Zeiss Inc, Oberkochen, Germany) modified with the monocular night-vision system (Owl Nitemare Third Generation; BE Meyers & Co, Inc, Redmond, Washington). The arrow points to the location of the slider housing the infrared bandpass filter.
Photomicrographs show retinas of rhodopsin-mutant dogs 15 days after subretinal injection of isotonic sodium chloride solution. With the use of the standard operating microscope light, the retinas showed extensive outer retinal and retina pigment epithelial degeneration in the injected (A and B) and noninjected (C and D) areas of different dogs. With the use of the night-vision system and infrared light in the fellow eyes, the retinal morphologic features remained normal in the injected areas (E and F) (hematoxylin-eosin; calibration marker, 50 μm).
Comparison of brightness settings between the OPMI6 and VISU160 operating microscopes (Carl Zeiss Inc, Oberkochen, Germany). The gray area shows the range of commonly used VISU160 settings (0.3-0.6) that were overlapped with the OPMI6 settings evaluated in this study (3.5-5.0).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.